Predict your next investment

Corporate Venture
FINANCE | Investment Firms & Funds
srone.com

See what CB Insights has to offer

Investments

297

Portfolio Exits

88

Funds

6

Service Providers

1

About SR One

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. SR One has a team of investment professionals, located in the US and UK. As a Team, its experience spans basic science, industry and the market. The firm takes an active role in its portfolio companies and work with management teams and its fellow venture investors to create significant value.

SR One Headquarter Location

161 Washington St #500

Conshohocken, Pennsylvania, 19428,

United States

610-567-1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SR One

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find SR One in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

SR One Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SR One Rank

Latest SR One News

Ancora Biotech Announces $60M Series A Co-Led by Lightspeed Venture Partners and SR One

Jun 23, 2022

June 9, 2022 – Client News Share This Page Gunderson Dettmer represented client Ancora Biotech, a California-based biotechnology company, in its $60 million Series A financing co-led by Lightspeed Venture Partners and SR One to help support the company’s clinical development of three multi-specific antibodies. The three antibodies include 1) TNB-486 a bispecific T cell engager that targets CD19 on cancer cells and binds to CD3 on T cells, 2) TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) a preclinical program (anti-HBsAg CD3 antibody) for the curative treatment of chronic hepatitis B infections. The company is led by CEO Roland Buelow, who was founder and CEO of Tenebio, and Roland’s son and CMO Ben Beulow. In a blog post published by Lightspeed Venture Partners, the co-lead investor said, “While Lightspeed often invests in early-stage preclinical programs, our past relationship with Roland and his team, their expertise in antibody innovation and deals, plus the appeal of having two programs already in the clinic made the investment opportunity one we could not pass up. The strength of the Ancora team, combined with the opportunity potential of the wide range of indications the company is pursuing, ultimately led to Lightspeed co-leading the series A, with Galym Imanbayev, MD, joining the board.” The Gunderson deal team was co-led by Michael Irvine, Colin Chapman, Steve Ray, and Nate Gray and included Brenden Glapion, Julie Mahoney, Scout Moran, Craig Oshlan and Doug Ikegami. Related People

SR One Investments

297 Investments

SR One has made 297 investments. Their latest investment was in Ancora Biotech as part of their Series A on June 6, 2022.

CBI Logo

SR One Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/9/2022

Series A

Ancora Biotech

$60M

Yes

3

6/8/2022

Series B

Mineralys Therapeutics

$118M

Yes

6

3/29/2022

Series B

Dren Bio

$65M

No

1

12/8/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/7/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/9/2022

6/8/2022

3/29/2022

12/8/2021

12/7/2021

Round

Series A

Series B

Series B

Series A

Series A

Company

Ancora Biotech

Mineralys Therapeutics

Dren Bio

Subscribe to see more

Subscribe to see more

Amount

$60M

$118M

$65M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

6

1

10

10

SR One Portfolio Exits

88 Portfolio Exits

SR One has 88 portfolio exits. Their latest portfolio exit was Arcellx on February 04, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/4/2022

IPO

$99M

Public

9

9/21/2021

Acquired

$99M

2

5/27/2021

Acq - Pending

$99M

2

4/1/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

3/26/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/4/2022

9/21/2021

5/27/2021

4/1/2021

3/26/2021

Exit

IPO

Acquired

Acq - Pending

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

9

2

2

10

10

SR One Acquisitions

2 Acquisitions

SR One acquired 2 companies. Their latest acquisition was Gryphon Therapeutics on February 25, 1999.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/25/1999

Series B

$99M

$44.25M

Acquired

10/2/1996

Private Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

2/25/1999

10/2/1996

Investment Stage

Series B

Private Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$44.25M

$99M

Note

Acquired

Subscribe to see more

Sources

10

SR One Fund History

6 Fund Histories

SR One has 6 funds, including SR One Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/19/2020

SR One Fund I

$500M

1

8/9/2013

Action Potential Venture Capital Fund

$99M

10

1/1/1985

S.R. One Ltd.

Subscribe to see more

Subscribe to see more

$99M

10

SR One Capital Fund I-A

10

GlaxoSmithKline Canadian Fund

Subscribe to see more

Subscribe to see more

10

Closing Date

11/19/2020

8/9/2013

1/1/1985

Fund

SR One Fund I

Action Potential Venture Capital Fund

S.R. One Ltd.

SR One Capital Fund I-A

GlaxoSmithKline Canadian Fund

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$500M

$99M

$99M

Sources

1

10

10

10

10

SR One Service Providers

1 Service Provider

SR One has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

SR One Team

11 Team Members

SR One has 11 team members, including current Chief Executive Officer, Simeon J. George.

Name

Work History

Title

Status

Simeon J. George

Chief Executive Officer

Current

Barbara J Dalton

EuclidSR Partners

President

Former

Jens W. Eckstein

Action Potential Venture Capital, Selectx Pharmaceuticals, TVM Capital Life Science, and Enanta Pharmaceuticals

President

Former

Russell G Greig

President

Former

Peter A Sears

President

Former

Name

Simeon J. George

Barbara J Dalton

Jens W. Eckstein

Russell G Greig

Peter A Sears

Work History

EuclidSR Partners

Action Potential Venture Capital, Selectx Pharmaceuticals, TVM Capital Life Science, and Enanta Pharmaceuticals

Title

Chief Executive Officer

President

President

President

President

Status

Current

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.